MSCLF 财务： Satellos Bioscience Inc AI 分析

主页

股票

MSCLF

财务数据

MSCLF 财务

Satellos Bioscience Inc

$5.63

-4.73%

$-0.28

收盘价：Apr 01, 16:00:00 GMT-4

$5.63

盘后：Apr 01, 20:00:00 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

MSCLF 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	0	0	0	0	0	0
营收同比增长 (YoY)	--	--	--	--	--	--
营收成本	--	--	--	--	--	--
毛利润	--	--	--	--	--	--
销售、一般及管理费用	6	5	4	3	2	0
研发	16	14	6	1	1	0
营业费用	24	20	11	6	4	1
其他非经营性收入 (费用)	--	--	--	0	0	0
税前利润	-21	-20	-11	-8	-15	-1
所得税费用	0	0	0	0	--	--
净利润	-21	-20	-11	-8	-15	-1
净利润增长	-16%	82%	38%	-47%	1,400%	--
稀释后流通股数	13.94	9.56	7.2	2.97	2	0.64
股份同比变动 (YoY)	48%	33%	142%	48%	213%	--
每股收益 (摊薄)	-1.57	-2.15	-1.62	-2.79	-7.72	-2.32
每股收益增长率	-43%	33%	-42%	-64%	233%	--
自由现金流	-48	-45	-23	-4	-5	0
每股自由现金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
营业利润率	0%	0%	0%	0%	0%	0%
净利率	0%	0%	0%	0%	0%	0%
自由现金流利润率	0%	0%	0%	0%	0%	0%
EBITDA	-24	-20	-11	-6	-4	-1
EBITDA 利润率	0%	0%	0%	0%	0%	0%
EBITDA 中的折旧与摊销	0	0	0	0	0	0
EBIT	-24	-20	-11	-6	-4	-1
EBIT 利润率	0%	0%	0%	0%	0%	0%
有效税率	0%	0%	0%	0%	--	--

Follow-Up Questions

Satellos Bioscience Inc 的关键财务报表是什么？



根据最新的财务报表（Form-10K），Satellos Bioscience Inc 的总资产为 $50，净损失为 $-20

MSCLF 的关键财务比率是什么？



Satellos Bioscience Inc 的流动比率是 16.66，净利 margin 为 0，每股销售为 $0。

Satellos Bioscience Inc 的收入按细分市场或地理位置如何划分？



Satellos Bioscience Inc 最大收入来源是 Long-term Care Insurance，在最近的收益报告中收入为 4,250,000,000。就地区而言， United States, Mexico, Bermuda and India 是 Satellos Bioscience Inc 的主要市场，收入为 7,295,000,000。

Satellos Bioscience Inc 是否盈利？



不，根据最新的财务报表，Satellos Bioscience Inc 的净损失为 $-20

Satellos Bioscience Inc 有负债吗？



是的，Satellos Bioscience Inc 的负债为 3

Satellos Bioscience Inc 的流通股有多少？



Satellos Bioscience Inc 的总流通股为 13.81

关键数据

前收盘价

$5.91

开盘价

$5.91

当日区间

$5.63 - $6.69

52周范围

$0.88 - $12.5

交易量

125.9K

平均成交量

12.1K

股息收益率

每股收益（TTM）

2.57

市值

$87.0M

什么是 SATELLOS BIOSCIENCE INC.？

Satellos Bioscience Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 14 full-time employees. The company went IPO on 2006-12-01. Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The firm is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. The company is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.

功能特性

资源